Pouschine Cook Leads Investment in Curexa Pharmacy

Vesey Street Capital Partners Majority Recapitalizes Inceptua Group

January 16, 2024

Healthcare Services

Vesey Street Capital Partners has completed a majority recapitalization of Luxembourg-headquartered Inceptua Group, a global pharmaceutical services provider specializing in clinical trial supplies and early access programs. As part of the transaction, industry veteran Doug Cook will join Inceptua as Executive Chairman to support the company's capability expansion and growth initiatives alongside CEO Stefan Fraenkel and founder Peter Krantz.

Audax Private Equity Makes Growth Investment in Pyramid Laboratories, Inc.

April 18, 2023

Pharmaceuticals

Audax Private Equity has made a growth investment in Pyramid Laboratories, Inc., a Costa Mesa, California-based CDMO that provides formulation development, analytical/stability testing, and aseptic fill-finish manufacturing for large-molecule biologics. The capital will support planned facility expansions to increase vial-filling capacity by more than 30% and syringe filling by more than 50%, and to scale Pyramid's clinical and commercial biologics manufacturing and service operations.

QHP Capital (NovaQuest PE) Acquires Lexitas Pharma Services

July 7, 2022

Healthcare Services

QHP Capital, the management company for NovaQuest Private Equity, has acquired Lexitas Pharma Services, a Durham-based full-service ophthalmology contract research organization (CRO). The private equity investment is intended to support Lexitas’s continued growth and capability expansion in ophthalmic clinical trial services for biopharmaceutical and medical device clients.

Capitala Group Exits Investment in Optio Rx

November 11, 2020

Healthcare Services

Capitala Group announced it has exited its senior secured debt and minority equity investment in Optio Rx, a national owner and operator of specialty compounding pharmacies. The original investment was made in partnership with Cold Bore Capital and funded Optio Rx's roll-up of specialty pharmacies serving fertility, veterinary, dermatology, hormone replacement and hospice markets.

Pfizer's Hospital Business Acquires Arixa Pharmaceuticals

October 22, 2020

Pharmaceuticals

Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.

Nicox S.A. Acquires Aciex Therapeutics, Inc.

July 2, 2014

Pharmaceuticals

Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.